Gilead Sciences | GILD - Net Income

Stock Price
149.43
Daily Change
3.20 2.19%
Monthly
23.13%
Yearly
52.42%
Q1 Forecast
137.58

Gilead Sciences reported $3.05B in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
J&J USD 5.12B 36M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
United Therapeutics USD 338.7M 29.2M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025